Marker Therapeutics was awarded a $2 million grant from NIH Small Business Innovation Research Program (SBIR) to support the clinical investigation of MT-601 in patients with lymphoma who have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback